Information about Vemaphar
My details
*
*
*

Company information

Status
Active

Enterprise number

BE0471.640.427

VAT liability
Yes
Established
30-03-2000
Last balance sheet year
2024
Company size
Medium-sized 0 FTE
Principal activity
Activities of holding companies
Health barometer
Credit limit
Detailpage

Are you looking for more information about this company?

  • Consult health at a glance

  • Choose quick insights or granular details

  • Get updates on important developments

7-day free trial, no credit card required.

Financial data from Vemaphar

2024 2023 2022 2021
Profit/Loss 195,836 -11 % 219,355 -32 % 322,748 86 % 173,412
Equity 1,758,531 13 % 1,562,696 16 % 1,343,341 32 % 1,020,592
Gross margin 307,099 45 % 211,209 36 % 155,776 -41 % 266,243

Publications from Vemaphar

Date Publication
30-12-2019 Modification Legal Form - Resignations - Appointments - General meeting (NL)
21-01-2014 Capital - Shares - Articles of Association (Translation, Coordination, Other Modifications, …) (NL)
16-06-2008 Designation - Registered Office - Capital - Shares - Modification Legal Form (NL)
04-02-2008 Resignations - Appointments (NL)
19-10-2006 Appointment(s) Renewal Mandate(s) (NL)

Frequently asked questions

What is the VAT number of Vemaphar?
The VAT number of Vemaphar is BE 0471.640.427.
Wat is the PEPPOL ID of Vemaphar?
The PEPPOL ID of Vemaphar is 0208:0471640427. Log in or start a free trial to see the full overview.
When was Vemaphar founded?
Vemaphar was founded on 30-03-2000.
What is the address of Vemaphar?
The current registered office of Vemaphar is located at Menenstraat 295, 8560 Wevelgem.
When was the last time Vemaphar filed their annual financial statements?
The most recent financial statements of Vemaphar were filed on 29-08-2025.
How many employees does Vemaphar have?
There are currently no employees working at Vemaphar or no workforce information is available.
What is the annual turnover of Vemaphar?
At the time of its most recent financial statements, Vemaphar did not publish any turnover figures. Vemaphar reported a gross margin of €307,099.44.